Exhibit 99.1

    Greatbatch Announces Completion of Enpath Medical Acquisition

    CLARENCE, N.Y.--(BUSINESS WIRE)--June 18, 2007--Greatbatch, Inc.
(NYSE: GB) announced today that it has successfully completed its
previously announced acquisition of Enpath Medical, Inc.

    Greatbatch's acquisition of Enpath Medical was structured as a
cash tender offer for the outstanding shares of Enpath Medical
followed by the merger of a Greatbatch acquisition subsidiary with and
into Enpath Medical, resulting in Enpath Medical becoming a wholly
owned, indirect subsidiary of Greatbatch. In the merger, outstanding
Enpath Medical shares not tendered in the tender offer were converted
into the right to receive $14.38 per share, in cash, without interest
and less any required withholding taxes.

    About Greatbatch

   Greatbatch, Inc. is a leading developer and manufacturer of
critical components used in implantable medical devices and other
technically demanding applications.

    About Enpath Medical

    Enpath Medical, Inc., headquartered in Plymouth, Minnesota, is a
leader in the design, development, manufacture and marketing of
percutaneous delivery systems and stimulation leads technologies. Its
proprietary products include venous vessel introducers, articulating
and fixed curve delivery catheters, epicardial and endocardial
stimulation leads, and other products for use in pacemaker,
defibrillator, catheter and infusion port procedures as well as
neuromodulation markets. Its products, which are primarily finished
goods, are sold worldwide through partnering relationships with other
medical device companies.

    CONTACT: Greatbatch, Inc.
             Anthony Borowicz
             Treasurer and Director, Investor Relations
             716-759-5809
             tborowicz@greatbatch.com